Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;23(5):1667-1675.
doi: 10.1016/j.jtha.2025.01.013. Epub 2025 Feb 10.

A rapid whole-blood adenosine triphosphate secretion test can be used to exclude platelet-dense granule deficiency

Collaborators, Affiliations
Free article

A rapid whole-blood adenosine triphosphate secretion test can be used to exclude platelet-dense granule deficiency

Minka Zivkovic et al. J Thromb Haemost. 2025 May.
Free article

Abstract

Background: Delta storage pool disease (δ-SPD) is a rare platelet function disorder (PFD) characterized by a deficiency of dense granules or defective granule secretion, leading to bleeding diathesis. Diagnostics of δ-SPD are difficult and lack standardization, leading to underestimation of its prevalence. Current diagnostic methods are based on granule content assays or lumi-aggregometry, which have limited availability. Therefore, there is an unmet need for a rapid, accessible test for δ-SPD.

Objectives: To evaluate the diagnostic value of a rapid whole-blood adenosine triphosphate (ATP) secretion test for δ-SPD.

Methods: ATP secretion after PAR-1 activating peptide (PAR-1 AP; TRAP-6) stimulation was assessed in whole blood using luminescence in 50 healthy controls, 22 patients with a suspected PFD other than storage pool disease (non-SPD) and 25 patients with δ-SPD and corrected for platelet count. Diagnostic value of the test was determined with C-statistics, sensitivity, specificity, likelihood ratios (LLRs), and predictive values (PVs).

Results: PAR-1 AP mediated ATP secretion in the rapid test was lower in δ-SPD than in healthy controls and non-SPD patients (P < .0001). The rapid test was able to discriminate between δ-SPD and non-SPD patients (C-statistic 0.88; 95% CI, 0.78-0.98). At a cutoff value of the highest value of the δ-SPD group, the sensitivity was 100% and the specificity was 64%. This cutoff value corresponded with a positive LLR of 2.75, an optimal negative LLR of 0.00, positive PV of 76%, and negative PV of 100%.

Conclusion: A whole-blood ATP secretion test can be used to exclude ẟ-SPD in patients presenting with a primary hemostasis defect.

Keywords: blood platelet disorder; diagnostic tests; luminescent assay; platelet function tests; platelet storage pool deficiency.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest M.Z.: no conflicts of interest. R.E.G.S.: The institution of R.E.G. Schutgens has received speaker’s fees and/or research grants from Bayer, CSL Behring, Hemab, Novartis, Novo Nordisk, Octapharma, Roche, Sobi, and Takeda. V.v.d.V.: no conflicts of interest. J.A.L.: no conflicts of interest. M.R.: employee of Synapse Research Institute. D.H.: employee of Synapse Research Institute. A.S.d.M.: no conflicts of interest. I.C.L.K.H.: no conflicts of interest. R.T.U.: The institution of R.T. Urbanus has received research grants from Hemab.

LinkOut - more resources